HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
Read original at benzingaStocks · News reference
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 8, 2026, 1:34 PM
- Checked
- Jul 8, 2026, 1:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses of $(0.39) per share
Read original at benzingaSatellos Gets FDA Fast Track Status For Duchenne Drug
Read original at benzinga